Appraisal of four novel approaches to the prevention and treatment of sepsis

American Journal of Health-System Pharmacy

Volumn 61, Issue 8, 2004, Pages 765-776

  Kumar, Atul ^a   Mann, Henry J ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Department of Pharmacy Practice   (United States)

Author keywords

Antiinflammatory agents; Drotrecogin alfa; Gases; Models; Oxygen; Sepsis; Steroids, cortico ; Toxicity

Indexed keywords

DROTRECOGIN; FLUDROCORTISONE; GLUCOSE; HYDROCORTISONE;

ADRENAL INSUFFICIENCY; BLEEDING; CORTICOTROPIN TEST; CRYPTIC SHOCK; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HEMODYNAMICS; HUMAN; OXYGEN THERAPY; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; SHOCK; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 8344251014     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.8.765     Document Type: Review

References (60)

1. Jacobi J. Pathophysiology of sepsis. Am J Health-Syst Pharm. 2002; 59(suppl 1): S3-8.
2. Van Amersfoort ES, Van Berkel TJ, Kuiper J. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev. 2003; 16:379-414.
3. Angus DC, Linde-Zwirble WT, Lidicker J et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associated costs of care. Crit Care Med. 2001; 29:1303-10.
4. Martin GS, Mannino DM, Eaton S et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003; 348:1546-54.
5. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001; 344:699-709.
6. Van Den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001; 345: 1359-67.
7. Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001; 345:1368-77.
8. Annane D, Sebille V, Charpentier C et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock, JAMA. 2002; 288:862-71.
9. Fourrier F, Chopin C, Goudemand J et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation: compared patterns of antithrombin III, protein C, and protein S deficiencies, Chest. 1992; 101:816-23.
10. Lorente JA, Garcia-Frade LJ, Landin L et al. Time course of hemostatic abnormalities in sepsis and its relation to outcome, Chest. 1993; 103:1536-42.
11. Boldt J, Papsdorf M, Rothe A et al. Changes of the hemostatic network in critically ill patients - is there a difference between sepsis, trauma, and neurosurgery patients? Crit Care Med. 2000; 28: 445-50.
12. Powars D, Larsen R, Johnson J et al. Epidemic meningococcemia and purpura fulminans with induced protein C deficiency. Clin Infect Dis. 1993; 17:254-61.
13. Ely EW, Laterre PF, Angus DC et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med. 2003; 31:12-9.
14. Xigris package insert. Indianapolis, IN: Lilly; 2003 Oct.
15. Bernard GR, Macias WL, Joyce DE et al. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit Care. 2003; 7:155-63.
16. Vincent JL, Angus DC, Artigas A et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med. 2003; 31:834-40.
17. McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin. 2001; 17:107-24.
18. Shangraw RE, Jahoor F, Miyoshi H et al. Differentiation between septic and post-burn insulin resistance. Metabolism. 1989; 38:983-9.
19. Fietsam R Jr, Bassett J, Glover JL. Complications of coronary artery surgery in diabetic patients. Am Surg. 1991; 57:551-7.
20. O'Neill PA, Davies I, Fullerton KJ et al. Stress hormone and blood glucose response following acute stroke in the elderly. Stroke. 1991; 22:842-7.
21. Scott JF, Robinson GM, French JM et al. Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycemia: the Glucose Insulin in Stroke Trial (GIST). Stroke. 1999; 30:793-9.
22. Van Den Berghe G, Wouters P, Bouillon R et al. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med. 2003; 31:359-66.
23. Klein S, Kinney J, Jeejeebhoy K et al. Nutrition support in clinical practice: review of published data and recommendations for future research directions: summary of a conference sponsored by the National Institutes of Health, American Society for Parenteral and Enteral Nutrition, and American Society for Clinical Nutrition. Am J Clin Nutr. 1997; 66:683-706.
24. Mazuski JE, Bailey JA, Shapiro MJ. Intensive insulin therapy in critically ill patients. N Engl J Med. 2002; 346:1586. Letter.
25. Dandona P, Aljada A, Mohanty P et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab. 2001; 86:3257-65.
26. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diab Complications, 2001; 15:44-54.
27. Kwoun MO, Ling PR, Lydon E et al. Immunologic effects of acute hyperglycemia in nondiabetic rats. JPEN J Parenter Enteral Nutr. 1997; 21:91-5.
28. Hirsch IB, Coviello A. Intensive insulin therapy in critically ill patients. N Engl J Med. 2002; 346:1586. Letter.
29. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation. 1997; 96:1152-6.
30. Lazar HL, Philippides G, Fitzgerald C et al. Glucose-insulin-potassium solutions enhance recovery after urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg. 1997; 113:354-60.
31. McCowen KC, Maykel JA, Bistrian BR. Intensive insulin therapy in critically ill patients. N Engl J Med. 2002; 346:1587, Letter.
32. Boyd O, Bennett ED. Enhancement of perioperative tissue perfusion as a therapeutic strategy for major surgery. New Horiz. 1996; 4:453-65.
33. Gattinoni L, Brazzi L, Pelosi P et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med. 1995; 333:1025-32.
34. Shoemaker WC. Goal-oriented hemodynamic therapy. N Engl J Med. 1996; 334:799. Letter.
35. Shoemaker WC, Appel PL, Kram HB et al. Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. Chest. 1988; 94:1176-86.
36. Boyd O, Grounds RM, Bennett ED. A randomized clinical trial of the effect of deliberate perioperative increase of oxygen delivery on mortality in high-risk surgical patients. JAMA. 1993; 270:2699-707.
37. Cronin L, Cook DJ, Carlet J et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med. 1995; 23:1430-9.
38. Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med. 1995; 23: 1294-303.
39. Rothwell PM, Udwadia ZF, Lawler PG. Cortisol response to corticotropin and survival in septic shock. Lancet. 1991; 337:582-3.
40. Soni A, Pepper GM, Wyrwinski PM et al. Adrenal insufficiency during septic shock: incidence, outcome and relationship to peripheral cytokine levels. Am J Med. 1995; 98:266-71.
41. Vincent JL, Abraham E, Annane D et al. Reducing mortality in sepsis: new directions. Crit Care. 2002; 6(suppl 3):S1-18.
42. Abroug F, Besbes L, Nouira S. Goal-directed therapy for severe sepsis. N Engl J Med. 2002; 346:1025. Letter.
43. Sarkar S, Kupfer Y, Tessler S. Goal-directed therapy for severe sepsis. N Engl J Med. 2002; 346:1025. Letter.
44. Rangel-Frausto MS, Pittet D, Costigan M et al. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA. 1995; 273:117-23.
45. Opal SM. Corticosteroids for patients with septic shock. JAMA. 2003; 289:41. Letter.
46. Bouachour G, Tirot P, Gouello JP et al. Adrenocortical function during septic shock. Intensive Care Med. 1995; 21:57-62.
47. Abraham E, Evans T. Corticosteroids and septic shock. JAMA. 2002; 288:886-7. Editorial.
48. Sessler CN. Steroids for septic shock. Chest. 2003; 123:482S-9S.
49. Annane D, Sebille V, Bellissant E. Reply. (Corticosteroids for patients with septic shock.) JAMA. 2003; 289:43-4. Letter.
50. Yildiz O, Doganay M, Aygen B et al. Physiological-dose steroid therapy in sepsis. Crit Care. 2002; 6:251-9.
51. Keh D, Boehnke T, Weber-Cartens S et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med. 2003; 167:512-20.
52. Zijlstra JG, van der Horst IC, Tulleken JE et al. Corticosteroids for patients with septic shock. JAMA. 2003; 289:42. Letter.
53. Bollaert PE, Fieux F, Charpentier C et al. Baseline cortisol levels, cortisol response to corticotropin, and prognosis in late septic shock. Shock. 2003; 19:13-5.
54. Marik PE, Zaloga GP. Adrenal insufficiency during septic shock. Crit Care Med. 2003; 31:141-5.
55. Annane D, Sebille V, Troche G et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA. 2000; 283:1038-45.
56. Yamashita S, Drynan J, Guest C et al. Comparison of low-dose (1 μg) with conventional dose cosyntropin (250 μg) for adrenal insufficiency testing in critical illness. Crit Care Med. 2001; 29(suppl): A164.
57. Zarkovic M, Ciric J, Stojanovic M et al. Optimizing the diagnostic criteria for standard (250-μg) and low-dose (1-μg) adrenocorticotropin tests in the assessment of adrenal function. J Clin Endocrinol Metab. 1999; 84:3170-3.
58. Dokmetas HS, Colak R, Kelestimur F et al. A comparison between the 1-μg adrenocorticotropin (ACTH) test, the short ACTH (250 μg) test, and the insulin tolerance test in the assessment of hypothalamo-pituitary-adrenal axis immediately after pituitary surgery. J Clin Endocrinol Metab. 2000; 85:3713-9.
59. Laterre PF, Levy H, Bates BM. Steroid use in PROWESS patients with septic shock. Paper presented at European Society of Intensive Care Medicine 16th Annual Congress. Amsterdam, Netherlands; 2003 Oct 7.
60. Warren HS, Suffredini AF, Eichacker PQ et al. Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med. 2002; 347:1027-30.